ArticleBMC endocrine disorders2025
Predictors of weight reduction effectiveness with liraglutide in diabetes mellitus type 2 patients: a retrospective cohort study.
Article in BMC endocrine disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Phenotypic and genomic frameworks for precision pharmacotherapy in obesity: a narrative review.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGLP-1 receptor agonists (GLP-1RAs) are effective for treating type 2 diabetes mellitus (T2DM) and promoting weight loss, but not all patients respond similarly. This study aimed to identify predictors of significant weight reduction at 6 months in T2DM patients treated with liraglutide. MATERIALS AND
methodsA retrospective analysis was conducted on 209 T2DM adults prescribed liraglutide at the Internal Medicine Department, Faculty of Medicine, Chiang Mai University between January 1, 2017, and December 31, 2022. Patients who could not tolerate or did not complete titration to 3.0 mg daily were excluded. Demographic, clinical, anthropometric, and biochemical data were obtained from electronic medical records. Logistic regression was used to identify clinical and biochemical factors associated with significant weight reduction (≥ 5% at 6 months), presented as odds ratios (ORs) with 95% confidence intervals (CIs). Statistical significance was set at p < 0.05.
resultsOf the 209 patients, 27.3% achieved significant weight reduction. Lower baseline body mass index (BMI) (OR 1.12, 95% CI 1.01–1.25, p = 0.036) and greater weight loss at 3 months (OR 2.22, 95% CI 1.67–3.03, p < 0.001) were significant predictors of weight reduction at 6 months, after adjusting for age, sex, baseline HbA1c, creatinine, systolic blood pressure, LDL cholesterol, and concomitant medications.
conclusionLower baseline BMI and early weight loss at 3 months predict significant weight reduction with liraglutide therapy. Identifying these simple, accessible predictors can improve patient selection and optimize weight control outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.